Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SNCA | P37840 | 14/20 | 0.59 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.56 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.56 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.56 |
| ▸ | SPR | P35270 | 1/20 | 0.52 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.52 |
| ▸ | MPO | P05164 | 2/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30487854 | 1.00 | SNCA (0.59) | SNCANOTUMMTNR1AMTNR1BSPR | |
| SCHEMBL30487855 | 1.00 | SNCA (0.59) | SNCANOTUMMTNR1AMTNR1BSPR | |
| SCHEMBL21809408 | 0.93 | SNCA (0.62) | SNCANOTUMMTNR1AMTNR1BSPR | |
| SCHEMBL892552 | 0.93 | SNCA (0.70) | SNCA | |
| SCHEMBL892796 | 0.93 | SNCA (0.70) | SNCANOTUM | |
| SCHEMBL21809407 | 0.91 | SNCA (0.57) | SNCANOTUMMTNR1AMTNR1BSPR | |
| SCHEMBL30487845 | 0.91 | SNCA (0.57) | SNCANOTUMMTNR1AMTNR1BSPR | |
| SCHEMBL30487846 | 0.91 | SNCA (0.57) | SNCANOTUMMTNR1AMTNR1BSPR | |
| SCHEMBL21809405 | 0.90 | SNCA (0.60) | SNCANOTUMMTNR1AMTNR1BSPR | |
| SCHEMBL30487835 | 0.90 | SNCA (0.60) | SNCANOTUMMTNR1AMTNR1BSPR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12178805-B2 | Inhibitors of PDE6Delta for use in the prevention and/or treatment of epilepsy and/or neurodegenerative disorders | REMYND N.V. (BE) | 2024-12-31 | — | — | US | claimed |
| US-11939324-B2 | Compounds for the treatment of epilepsy, neurodegenerative disorders and other CNS disorders | REMYND N.V. (BE) | 2024-03-26 | — | — | US | claimed |
| EP-3621963-B1 | COMPOUNDS FOR THE TREATMENT OF EPILEPSY, NEURODEGENERATIVE DISORDERS AND OTHER CNS DISORDERS | REMYND N V (BE) | 2024-01-24 | — | — | EP | claimed |
| US-20230099111-A1 | COMPOUNDS FOR THE TREATMENT OF EPILEPSY, NEURODEGENERATIVE DISORDERS AND OTHER CNS DISORDERS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2023-03-30 | — | — | US | claimed |
| US-11548881-B2 | Compounds for the treatment of epilepsy, neurodegenerative disorders and other CNS disorders | REMYND N.V. (BE) | 2023-01-10 | — | — | US | claimed |
| US-20200253934-A1 | INHIBITORS OF PDE6DELTA FOR USE IN THE PREVENTION AND/OR TREATMENT OF EPILEPSY AND/OR NEURODEGENERATIVE DISORDERS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2020-08-13 | — | — | US | claimed |
| US-20200095238-A1 | COMPOUNDS FOR THE TREATMENT OF EPILEPSY, NEURODEGENERATIVE DISORDERS AND OTHER CNS DISORDERS | CISTIM (BE) | 2020-03-26 | — | — | US | claimed |
| US-12178805-B2 | Inhibitors of PDE6Delta for use in the prevention and/or treatment of epilepsy and/or neurodegenerative disorders | REMYND N.V. (BE) | 2024-12-31 | — | — | US | disclosed |
| US-11939324-B2 | Compounds for the treatment of epilepsy, neurodegenerative disorders and other CNS disorders | REMYND N.V. (BE) | 2024-03-26 | — | — | US | disclosed |
| EP-3621963-B1 | COMPOUNDS FOR THE TREATMENT OF EPILEPSY, NEURODEGENERATIVE DISORDERS AND OTHER CNS DISORDERS | REMYND N V (BE) | 2024-01-24 | — | — | EP | disclosed |
| EP-3621963-B1 | COMPOUNDS FOR THE TREATMENT OF EPILEPSY, NEURODEGENERATIVE DISORDERS AND OTHER CNS DISORDERS | REMYND N V (BE) | 2024-01-24 | — | — | EP | disclosed |
| CN-110650955-B | Compounds for the treatment of epilepsy, neurodegenerative disorders and other CNS disorders | 瑞敏德股份有限公司 | 2023-07-25 | — | — | CN | disclosed |
| US-20230099111-A1 | COMPOUNDS FOR THE TREATMENT OF EPILEPSY, NEURODEGENERATIVE DISORDERS AND OTHER CNS DISORDERS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2023-03-30 | — | — | US | disclosed |
| US-11548881-B2 | Compounds for the treatment of epilepsy, neurodegenerative disorders and other CNS disorders | REMYND N.V. (BE) | 2023-01-10 | — | — | US | disclosed |
| US-11548881-B2 | Compounds for the treatment of epilepsy, neurodegenerative disorders and other CNS disorders | REMYND N.V. (BE) | 2023-01-10 | — | — | US | disclosed |
| US-20200253934-A1 | INHIBITORS OF PDE6DELTA FOR USE IN THE PREVENTION AND/OR TREATMENT OF EPILEPSY AND/OR NEURODEGENERATIVE DISORDERS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2020-08-13 | — | — | US | disclosed |
| US-20200253934-A1 | INHIBITORS OF PDE6DELTA FOR USE IN THE PREVENTION AND/OR TREATMENT OF EPILEPSY AND/OR NEURODEGENERATIVE DISORDERS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2020-08-13 | — | — | US | disclosed |
| US-20200095238-A1 | COMPOUNDS FOR THE TREATMENT OF EPILEPSY, NEURODEGENERATIVE DISORDERS AND OTHER CNS DISORDERS | CISTIM (BE) | 2020-03-26 | — | — | US | disclosed |
| CN-110650955-A | Compounds for the treatment of epilepsy, neurodegenerative disorders and other CNS disorders | 瑞敏德股份有限公司 | 2020-01-03 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200095238-A1 | COMPOUNDS FOR THE TREATMENT OF EPILEPSY, NEURODEGENERATIVE DISORDERS AND OTHER CNS DISORDERS | MAPT, PSEN1, PSEN2 | SNCA 34/4885NOTUM 1671/4885MTNR1A 86/4885 |
| US-12178805-B2 | Inhibitors of PDE6Delta for use in the prevention and/or treatment of epilepsy and/or neurodegenerative disorders | PDE4A, PDE12, PDE2A | SNCA 294/4885NOTUM 2205/4885MTNR1A 1212/4885 |
| US-20230099111-A1 | COMPOUNDS FOR THE TREATMENT OF EPILEPSY, NEURODEGENERATIVE DISORDERS AND OTHER CNS DISORDERS | MAPT, PSEN1, PSEN2 | SNCA 34/4885NOTUM 1671/4885MTNR1A 86/4885 |
| US-11548881-B2 | Compounds for the treatment of epilepsy, neurodegenerative disorders and other CNS disorders | MAPT, PSEN1, PSEN2 | SNCA 34/4885NOTUM 1671/4885MTNR1A 86/4885 |
| US-20200253934-A1 | INHIBITORS OF PDE6DELTA FOR USE IN THE PREVENTION AND/OR TREATMENT OF EPILEPSY AND/OR NEURODEGENERATIVE DISORDERS | PDE4A, PDE12, PDE2A | SNCA 294/4885NOTUM 2205/4885MTNR1A 1212/4885 |
| US-11939324-B2 | Compounds for the treatment of epilepsy, neurodegenerative disorders and other CNS disorders | MAPT, PSEN1, PSEN2 | SNCA 34/4885NOTUM 1671/4885MTNR1A 86/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.